ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma.Frontiers in immunology · 2026Article
- Article
- Helical reconstruction of VP39 reveals principles for baculovirus nucleocapsid assembly.Nature communications · 2024Article
- Helical reconstruction of VP39 reveals principles for baculovirus nucleocapsid assembly.bioRxiv : the preprint server for biology · 2023Article
- Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.Transplant international : official journal of the European Society for Organ Transplantation · 2022Review
- Recent progress in the research of suicide gene therapy for malignant glioma.Neurosurgical review · 2021Review
- Identification of differentially expressed proteins and clinicopathological significance of HMGB2 in cervical cancer.Clinical proteomics · 2021Article
- Baculoviruses in Gene Therapy and Personalized Medicine.Biologics : targets & therapy · 2021Review
- Viral vector: potential therapeutic for glioblastoma multiforme.Cancer gene therapy · 2020Review
- Biological functions and theranostic potential of HMGB family members in human cancers.Therapeutic advances in medical oncology · 2020Review
- Review
- Progress and problems with the use of suicide genes for targeted cancer therapy.Advanced drug delivery reviews · 2016Review
- Review
- A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.Stem cells international · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance.Neuro-oncology · 2013Article
- An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.Cell reports · 2013Article
- Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma.Oncology letters · 2013Article
- High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.Cancer biology & therapy · 2013Article
- Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy.Gene therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achievement of specific tumor cell targeting remains a challenge for glioma gene therapy. We observed that the human high mobility group box2 (HMGB2) gene had a low level of expression in normal human brain tissues, but was significantly upregulated in glioblastoma tissues. With progressive truncation of a 5'-upstream sequence of the HMGB2 gene, we identified a 0.5-kb fragment displaying a high transcriptional activity in glioblastoma cells, but a low activity in normal brain cells. To test the feasibility of using the HMGB2 promoter sequence in targeted cancer therapy, we constructed a baculoviral vector expressing the herpes simplex virus thymidine kinase (HSVtk) gene driven by the HMGB2 promoter. Transduction with the viral vector induced cell death in glioblastoma cell lines in the presence of ganciclovir (GCV), but did not affect the survival of human astrocytes and neurons. In a mouse xenograft model, intratumor injection of the baculoviral vector suppressed the growth of human glioblastoma cells and prolonged the survival of tumor-bearing mice. Our results suggest that the novel 5' sequence of HMGB2 gene has a potential to be used as an efficient, tumor-selective promoter in targeted vectors for glioblastoma gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.